OBI gains ThioBridge linker tech from Abzena for OBI-999 and other ADCs

Abzena plc (LSE:ABZA) granted OBI Pharma Inc. (TPEx:4174) exclusive, worldwide rights to ThioBridge antibody drug conjugate (ADC) linker- technology which OBI will use to develop its preclinical cancer candidate OBI-999 and other undisclosed ADCs to treat cancer. As part of a concurrent deal, Abzena will manufacture OBI-999 and other ADCs for OBI.

Abzena will receive an undisclosed upfront payment and is eligible for up to £128 million ($167.3 million) in development, regulatory and commercialization milestones, plus royalties. ...